Deucravacitinib for the Treatment of Palmoplantar Pustulosis
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with
PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits
every 4 weeks.